685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL

Bibliographic Details
Main Authors: Koby Kidder, Rita N Barcia, Stephen Fogelson, Candida Fratazzi, Nathanael McCurley
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
_version_ 1827764039690747904
author Koby Kidder
Rita N Barcia
Stephen Fogelson
Candida Fratazzi
Nathanael McCurley
author_facet Koby Kidder
Rita N Barcia
Stephen Fogelson
Candida Fratazzi
Nathanael McCurley
author_sort Koby Kidder
collection DOAJ
first_indexed 2024-03-11T10:59:07Z
format Article
id doaj.art-55ace57f7dfe4f9dbeeb95728fafee59
institution Directory Open Access Journal
issn 2051-1426
language English
last_indexed 2024-03-11T10:59:07Z
publishDate 2023-11-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj.art-55ace57f7dfe4f9dbeeb95728fafee592023-11-12T13:45:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0685685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHLKoby Kidder0Rita N Barcia1Stephen Fogelson2Candida Fratazzi3Nathanael McCurley4Aff266 grid.256304.60000000419367400Georgia State University Atlanta GA USA1SIRPant Immunotherapeutics, Hummelstown, PA, USA2Develotron, LLC, Hillsborough, NH, USA3BBCR, Cambridge, MA, USA1SIRPant Immunotherapeutics, Hummelstown, PA, USA
spellingShingle Koby Kidder
Rita N Barcia
Stephen Fogelson
Candida Fratazzi
Nathanael McCurley
685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
Journal for ImmunoTherapy of Cancer
title 685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
title_full 685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
title_fullStr 685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
title_full_unstemmed 685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
title_short 685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
title_sort 685 a first in human phase 1 2 clinical trial of sirpαlow activated macrophages sirpant m for the treatment of r r nhl
work_keys_str_mv AT kobykidder 685afirstinhumanphase12clinicaltrialofsirpalowactivatedmacrophagessirpantmforthetreatmentofrrnhl
AT ritanbarcia 685afirstinhumanphase12clinicaltrialofsirpalowactivatedmacrophagessirpantmforthetreatmentofrrnhl
AT stephenfogelson 685afirstinhumanphase12clinicaltrialofsirpalowactivatedmacrophagessirpantmforthetreatmentofrrnhl
AT candidafratazzi 685afirstinhumanphase12clinicaltrialofsirpalowactivatedmacrophagessirpantmforthetreatmentofrrnhl
AT nathanaelmccurley 685afirstinhumanphase12clinicaltrialofsirpalowactivatedmacrophagessirpantmforthetreatmentofrrnhl